ReviewFrontiers in neurology2019
Medications, Deep Brain Stimulation, and Other Factors Influencing Impulse Control Disorders in Parkinson's Disease.
Review in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 58 citations in OpenAlex.
- Sexual dysfunction in movement disorders: prevalence, clinical features, associated factors and management.Clinical parkinsonism & related disorders · 2026Review
- Dopaminergic therapy disrupts decision-making in impulsive-compulsive Parkinsonian patients.Annals of clinical and translational neurology · 2025Article
- Clinically probable RBD is an early predictor of malignant non-motor Parkinson's disease phenotypes.NPJ Parkinson's disease · 2025Article
- Impulse control disorders in Parkinson's disease: What's new?Journal of neurology · 2025Review
- Subthalamic control of impulsive actions: insights from deep brain stimulation in Parkinson's disease.Brain : a journal of neurology · 2024Review
- The Association of Antidepressant Use and Impulse Control Disorder in Parkinson's Disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2024Observational
- Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson's Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better?Clinical parkinsonism & related disorders · 2024Article
- Improving Documentation of Impulse Control Disorders at a Movement Disorder Program During the COVID-19 Pandemic.Neurology. Clinical practice · 2023Article
- Weight and survival after deep brain stimulation for Parkinson's disease.Parkinsonism & related disorders · 2023Article
- Impulse Control Disorders in the Polish Population of Patients with Parkinson's Disease.Medicina (Kaunas, Lithuania) · 2023Article
- Course of Impulse Control Disorder Symptoms in Parkinson's Disease: Deep Brain Stimulation Versus Medications.Movement disorders clinical practice · 2023Article
- Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment.Clinical parkinsonism & related disorders · 2023Review
- Analysis of Influencing Factors of Apathy in Patients with Parkinson's Disease.Brain sciences · 2022Article
- Distinct Roles of the Human Subthalamic Nucleus and Dorsal Pallidum in Parkinson's Disease Impulsivity.Biological psychiatry · 2022Article
- A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies.Journal of Parkinson's disease · 2022Review
- Trait Anxiety as a Risk Factor for Impulse Control Disorders in de novo Parkinson's Disease.Journal of Parkinson's disease · 2022Article
- The neuropsychiatry of Parkinson's disease: advances and challenges.The Lancet. Neurology · 2022Review
- Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease.Journal of neurology, neurosurgery, and psychiatry · 2021Article
- Impulse Control Disorders in Parkinson's Disease: Has COVID-19 Related Lockdown Been a Trigger?Movement disorders clinical practice · 2021Article
- Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson's Disease.Frontiers in neuroscience · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Impulse control disorders (ICDs) in Parkinson's disease (PD) have a high cumulative incidence and negatively impact quality of life. ICDs are influenced by a complex interaction of multiple factors. Although it is now well-recognized that dopaminergic treatments and especially dopamine agonists underpin many ICDs, medications alone are not the sole cause. Susceptibility to ICD is increased in the setting of PD. While causality can be challenging to ascertain, a wide range of modifiable and non-modifiable risk factors have been linked to ICDs. Common characteristics of PD patients with ICDs have been consistently identified across many studies; for example, males with an early age of PD onset and dopamine agonist use have a higher risk of ICD. However, not all cases of ICDs in PD can be directly attributable to dopamine, and studies have concluded that additional factors such as genetics, smoking, and/or depression may be more predictive. Beyond dopamine, other ICD associations have been described but remain difficult to explain, including deep brain stimulation surgery, especially in the setting of a reduction in dopaminergic medication use. In this review, we will summarize the demographic, genetic, behavioral, and clinical contributions potentially influencing ICD onset in PD. These associations may inspire future preventative or therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.